ArticleJournal of cutaneous pathology2026
Diffuse CD30-Positive Cutaneous Infiltrate in a Clinically Suspected Hidradenitis Suppurativa Lesion: Histopathologic and Diagnostic Challenges.
Article in Journal of cutaneous pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder affecting apocrine gland-bearing areas. We report a 38-year-old male with a lesion in the left axilla, initially clinically interpreted as HS and resistant to antibiotics. Surgical excision and biopsy revealed a dense dermal and subcutaneous infiltrate of large atypical lymphoid cells with strong and diffuse CD30 expression (~80%-90% of tumor cells), CD4 positivity, ALK-negativity, and loss of pan-T-cell markers, consistent with anaplastic large cell lymphoma (ALCL). While the lesion was initially considered primary cutaneous, regional lymph node involvement and FDG-avid sites on PET created diagnostic uncertainty regarding systemic disease. The patient received multi-agent systemic chemotherapy followed by autologous stem cell transplantation, achieving complete metabolic remission. This case highlights the histopathologic challenges of diagnosing CD30-positive lymphoid infiltrates in the context of chronic inflammatory skin disease, particularly when lesions are initially clinically misinterpreted as benign inflammatory conditions such as HS. Recognition of diffuse CD30 positivity, cytologic atypia, subcutaneous involvement, and loss of pan-T-cell markers is critical for distinguishing malignant from reactive lymphoid infiltrates. Early biopsy, immunophenotypic analysis, and clinicopathologic correlation are essential to guide appropriate management in atypical or treatment-resistant lesions. Rather than demonstrating a novel association with HS, this report emphasizes diagnostic and classification challenges at the interface between primary cutaneous and systemic ALCL, which are of direct relevance to cutaneous pathologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.